Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2008
Adalimumab is a recombinant human IgG1 monoclonal antibody specific for tumor necrosis factor α (TNF-α). Pharmacologic blockade of TNF-α has proven beneficial in a variety of chronic inflammatory conditions, including rheumatoid arthritis and psoriasis.1 It has also been successfully used in the treatment of pyoderma gangrenosum,2 a noninfectious skin disorder frequently associated with rheumatoid arthritis, ulcerative colitis, or hematologic malignancy. A growing number of adverse skin reactions to anti–TNF-α agents, including local reactions at the injection site, nonspecific rashes, isolated cases of bullous skin lesions, leukocytoclastic vasculitis,3 and erythema multiforme,4 have been reported. Moreover, development of psoriasis5 during anti–TNF-α treatment has been observed.
Stichenwirth M, Riedl E, Pehamberger H, Tappeiner G. Pyoderma Gangrenosum in a Patient With Seronegative Rheumatoid Arthritis During Therapy With Adalimumab: Toxic Effects of Adalimumab or Failure of Adalimumab to Prevent the Onset of This Phenomenon? Arch Dermatol. 2008;144(6):817–818. doi:10.1001/archderm.144.6.817
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: